Stem Cell Treatment for Cerebral Palsy

Stem Cell Treatment for Cerebral Palsy

Stem Cell Treatments for Cerebral Palsy are Currently Available at SIRM

Because Cerebral Palsy is a condition that encompasses a group of non-progressive, non-contagious motor conditions that cause physical disability in human development, we aim to treat it with Stem Cell Therapy.

Cerebral refers to the cerebrum, which is the affected area of the brain (although the disorder most likely involves connections between the cortex and other parts of the brain such as the cerebellum), and palsy refers to disorder of movement. Cerebral palsy is caused by damage to the motor control centers of the developing brain and can occur during pregnancy, during childbirth or after birth up to about age three. Resulting limits in movement and posture cause activity limitation and are often accompanied by disturbances of sensation, depth perception and other sight-based perceptual problems, communication ability; impairments can also be found in cognition, and epilepsy is found in about one-third of cases. CP, no matter what the type, is often accompanied by secondary musculoskeletal problems that arise as a result of the underlying etiology.

Cerebral Palsy Stem Cell Treatment

Asphyxia, Infections, and Inflammation during Intrauterine development seemed to be the causes.

There are 4 types:

  1. Spastic - 80% and most common; hypertonic and have what is essentially a neuromuscular mobility impairment (rather than hypotonia or paralysis) stemming from an upper motor neuron lesion in the brain as well as the corticospinal tract or the motor cortex. This damage impairs the ability of some nerve receptors in the spine to properly receive gamma amino butyric acid, leading to hypertonia in the muscles signaled by those damaged nerves.
  2. Ataxic - caused by damage to the cerebellum, and it is common for individuals to have difficulty with visual and/or auditory processing.
  3. Dyskinetic - is mixed muscle tone – both hypertonia and hypotonia mixed with involuntary motions. People with Dyskinetic CP have trouble holding themselves in an upright, steady position for sitting or walking, and often show involuntary motions.
  4. Mixed - A combination of the above

Cerebral Palsy Stem Cell Treatment and stem cell therapy. Cerebral Palsy treatment studies and stem cell protocols:

Related Articles Induction of regional chemokine expression in response to human umbilical cord blood cell infusion in the neonatal mouse ischemia-reperfusion brain injury model. PLoS One. 2019;14(9):e0221111 Authors: Baba N, Wang F, Iizuka M, Shen Y, Yamashita T, Takaishi K, Tsuru E, Matsushima S, Miyamura M, Fujieda M, Tsuda M, Sagara Y, Maeda N Abstract Regenerative medicine using umbilical cord blood (UCB) cells shows promise for the treatment of cerebral palsy. Although the efficacy of this therapy has been seen in the clinic, the mechanisms by which UCB cells interact and aid in the improvement of symptoms are not clear. We explored the chemokine expression profile in damaged brain tissue in the neonatal mouse ischemia-reperfusion (IR) brain injury model that was infused with human UCB (hUCB) cells. IR brain injury was induced in 9-day-old NOD/SCID mice. hUCB cells were administered 3 weeks post brain injury. Chemokine expression profiles in the brain extract were determined at various time points. Inflammatory chemokines such as CCL1, CCL17, and CXCL12 were transiently upregulated by 24 hours post brain injury. Upregulation of other chemokines, including CCL5, CCL9, and CXCL1 were prolonged up to 3 weeks post brain injury, but most chemokines dissipated over time. There were marked increases in levels of CCL2, CCL12, CCL20, and CX3CL1 in response to hUCB cell treatment, which might be related to the new recruitment and differentiation of neural stem cells, leading to the induction of tissue regeneration. We propose that the chemokine expression profile in the brain shifted from responding to tissue damage to inducing tissue regeneration. hUCB cell administration further enhanced the production of chemokines, and chemokine networks may play an active role in tissue regeneration in neonatal hypoxic-ischemic brain injury. PMID: 31483787 [PubMed - in process]
Read more...

Quick Contact Form